Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis

Stroke

Volumn 47, Issue 5, 2016, Pages 1364-1367

  Joundi, Raed A ^a   Cipriano, Lauren E ^b,c   Sposato, Luciano A ^d   Saposnik, Gustavo ^a,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

atrial fibrillation; CHA2DS2 VASc; ischemic stroke; meta analysis; stroke

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL DECISION MAKING; COHORT ANALYSIS; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VASC SCORE; COMPLICATION; SEVERITY OF ILLNESS INDEX; STROKE;

ATRIAL FIBRILLATION; BRAIN ISCHEMIA; HUMANS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84961907955     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012609     Document Type: Review

References (18)

1. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
4. Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225-232. doi: 10.1016/j.jacc.2014.10.052.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413. doi: 10.1093/europace/eus305.
6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76. doi: 10.1016/j.jacc.2014.03.022.
7. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14-21. doi: 10.1161/CIRCOUTCOMES.110.958108.
8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
9. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat. 1998;52:119.
10. Paule R, Mandel J. Consensus values and weighting factors. J Res Natl Bur Stand. 1982;87:377-385.
11. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584-589. doi: 10.1160/TH11-11-0784.
12. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:1658-1665. doi: 10.1016/j.jacc.2014.06.1203.
13. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298-2307. doi: 10.1161/CIRCULATIONAHA.111.055079.
14. Huang D, Anguo L, Yue WS, Yin L, Tse HF, Siu CW. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2-VASc score of 1. Pacing Clin Electrophysiol. 2014;37:1442-1447. doi: 10.1111/pace.12445.
15. Komatsu T, Tachibana H, Satoh Y, Ozawa M, Kunugita F, Ueda H, et al. Relationship between CHA(2)DS(2)-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation not receiving anticoagulant therapy. J Cardiol. 2012;59:321-328. doi: 10.1016/j.jjcc.2012.01.003.
16. Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes. 2012;5:335-342. doi: 10.1161/CIRCOUTCOMES.111.964023.
17. Suzuki S, Yamashita T, Okumura K, Atarashi H, Akao M, Ogawa H, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015;79:432-438. doi: 10.1253/circj.CJ-14-1131.
18. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.